Myeloid-derived suppressor cells: General characteristics and relevance to clinical management of pancreatic cancer

Current Cancer Drug Targets

Volumn 11, Issue 6, 2011, Pages 734-751

  Goedegebuure, P ^a   Mitchem, J B ^a   Porembka, M R ^a   Tan, M C B ^a   Belt, B A ^a   Wang Gillam, A ^a   Gillanders, W E ^a   Hawkins, W G ^a   Linehan, D C ^a  

^a USA   (United States)

Author keywords

Bone marrow; Immune suppression; Metastasis; Myeloid derived suppressor cells; Pancreatic cancer

Indexed keywords

BARDOXOLONE METHYL; BEVACIZUMAB; CALGRANULIN A; CALGRANULIN B; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; CD11B ANTIGEN; CD14 ANTIGEN; CD15 ANTIGEN; CD31 ANTIGEN; COLECALCIFEROL; CYCLOOXYGENASE 2 INHIBITOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; GELATINASE B; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; K RAS PROTEIN; MESOTHELIN; MUCIN 1; RETINOIC ACID; SUNITINIB; T LYMPHOCYTE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN RECEPTOR 1; VERY LATE ACTIVATION ANTIGEN 4; ZOLEDRONIC ACID;

ADVANCED CANCER; ANGIOGENESIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER PATIENT; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; HEMATOPOIETIC SYSTEM; HUMAN; IMMUNITY; INNATE IMMUNITY; KIDNEY CARCINOMA; LYMPHOCYTE PROLIFERATION; MEMORY CELL; METASTASIS; MYELOID DERIVED SUPPRESSOR CELL; MYELOID PROGENITOR CELL; NONHUMAN; PANCREAS CANCER; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

ADENOCARCINOMA; ANIMALS; GRANULOCYTES; HUMANS; MYELOID CELLS; PANCREATIC NEOPLASMS;

EID: 79959966013     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800911796191024     Document Type: Article

References (206)

1. Jemal, A.; Siegel, R.; Xu, J.; Ward, E. Cancer statistics, 2010. CA Cancer J. Clin. 2010, 60, 277-300.
2. Cress, R. D.; Yin, D.; Clarke, L.; Bold, R.; Holly, E. A. Survival among patients with adenocarcinoma of the pancreas: a populationbased study (United States). Cancer Causes Control 2006, 17, 403-409.
3. Garcea, G.; Dennison, A. R.; Pattenden, C. J.; Neal, C. P.; Sutton, C. D.; Berry, D. P. Survival following curative resection for pancreatic ductal adenocarcinoma. A systematic review of the literature. J.O.P. 2008, 9, 99-132.
4. Winter, J. M.; Cameron, J. L.; Campbell, K. A.; Arnold, M. A.; Chang, D. C.; Coleman, J.; Hodgin, M. B.; Sauter, P. K.; Hruban, R. H.; Riall, T. S.; Schulick, R. D.; Choti, M. A.; Lillemoe, K. D.; Yeo, C. J. 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J. Gastrointest. Surg. 2006, 10, 1199-1210.
5. Burris, H. A., 3rd; Moore, M. J.; Andersen, J.; Green, M. R.; Rothenberg, M. L.; Modiano, M. R.; Cripps, M. C.; Portenoy, R. K.; Storniolo, A. M.; Tarassoff, P.; Nelson, R.; Dorr, F. A.; Stephens, C. D.; Von Hoff, D. D. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 1997, 15, 2403-2413.
6. Mackenzie, R. P.; McCollum, A. D. Novel agents for the treatment of adenocarcinoma of the pancreas. Expert Rev. Anticancer Ther. 2009, 9, 1473-1485.
7. Moore, M. J.; Goldstein, D.; Hamm, J.; Figer, A.; Hecht, J. R.; Gallinger, S.; Au, H. J.; Murawa, P.; Walde, D.; Wolff, R. A.; Campos, D.; Lim, R.; Ding, K.; Clark, G.; Voskoglou-Nomikos, T.; Ptasynski, M.; Parulekar, W. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 2007, 25, 1960-1966.
8. Picozzi, V. J.; Kozarek, R. A.; Traverso, L. W. Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am. J. Surg. 2003, 185, 476-480.
9. Linehan, D. C.; Tan, M. C.; Strasberg, S. M.; Drebin, J. A.; Hawkins, W. G.; Picus, J.; Myerson, R. J.; Malyapa, R. S.; Hull, M.; Trinkaus, K.; Tan, B. R., Jr. Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: a single-institution phase II study. Ann. Surg. 2008, 248, 145-151.
10. Neoptolemos, J. P.; Stocken, D. D.; Friess, H.; Bassi, C.; Dunn, J. A.; Hickey, H.; Beger, H.; Fernandez-Cruz, L.; Dervenis, C.; Lacaine, F.; Falconi, M.; Pederzoli, P.; Pap, A.; Spooner, D.; Kerr, D. J.; Buchler, M. W. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N. Engl. J. Med. 2004, 350, 1200-1210.
11. Oettle, H.; Post, S.; Neuhaus, P.; Gellert, K.; Langrehr, J.; Ridwelski, K.; Schramm, H.; Fahlke, J.; Zuelke, C.; Burkart, C.; Gutberlet, K.; Kettner, E.; Schmalenberg, H.; Weigang-Koehler, K.; Bechstein, W. O.; Niedergethmann, M.; Schmidt-Wolf, I.; Roll, L.; Doerken, B.; Riess, H. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007, 297, 267-277.
12. Regine, W. F.; Winter, K. A.; Abrams, R. A.; Safran, H.; Hoffman, J. P.; Konski, A.; Benson, A. B.; Macdonald, J. S.; Kudrimoti, M. R.; Fromm, M. L.; Haddock, M. G.; Schaefer, P.; Willett, C. G.; Rich, T. A. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 2008, 299, 1019-1026.
13. Evans, D. B.; Varadhachary, G. R.; Crane, C. H.; Sun, C. C.; Lee, J. E.; Pisters, P. W.; Vauthey, J. N.; Wang, H.; Cleary, K. R.; Staerkel, G. A.; Charnsangavej, C.; Lano, E. A.; Ho, L.; Lenzi, R.; Abbruzzese, J. L.; Wolff, R. A. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J. Clin. Oncol. 2008, 26, 3496-3502.
14. Varadhachary, G. R.; Wolff, R. A.; Crane, C. H.; Sun, C. C.; Lee, J. E.; Pisters, P. W.; Vauthey, J. N.; Abdalla, E.; Wang, H.; Staerkel, G. A.; Lee, J. H.; Ross, W. A.; Tamm, E. P.; Bhosale, P. R.; Krishnan, S.; Das, P.; Ho, L.; Xiong, H.; Abbruzzese, J. L.; Evans, D. B. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J.Clin. Oncol. 2008, 26, 3487-3495.
15. Veltkamp, S. A.; Pluim, D.; van Eijndhoven, M. A.; Bolijn, M. J.; Ong, F. H.; Govindarajan, R.; Unadkat, J. D.; Beijnen, J. H.; Schellens, J. H. New insights into the pharmacology and cytotoxicity of gemcitabine and 2',2'-difluorodeoxyuridine. Mol. Cancer Ther. 2008, 7, 2415-2425.
16. Suzuki, E.; Kapoor, V.; Jassar, A. S.; Kaiser, L. R.; Albelda, S. M. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin. Cancer Res. 2005, 11, 6713-6721.
17. Le, H. K.; Graham, L.; Cha, E.; Morales, J. K.; Manjili, M. H.; Bear, H. D. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. Int. Immunopharmacol. 2009, 9, 900-909.
18. Whiteside, T. L. The tumor microenvironment and its role in promoting tumor growth. Oncogene 2008, 27, 5904-5912.
19. Pages, F.; Galon, J.; Dieu-Nosjean, M. C.; Tartour, E.; Sautes-Fridman, C.; Fridman, W. H. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 2009, 29, 1093-1102.
20. Galon, J.; Costes, A.; Sanchez-Cabo, F.; Kirilovsky, A.; Mlecnik, B.; Lagorce-Pages, C.; Tosolini, M.; Camus, M.; Berger, A.; Wind, P.; Zinzindohoue, F.; Bruneval, P.; Cugnenc, P. H.; Trajanoski, Z.; Fridman, W. H.; Pages, F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313, 1960-1964.
21. Galon, J.; Fridman, W. H.; Pages, F. The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res. 2007, 67, 1883-1886.
22. Coussens, L. M.; Werb, Z. Inflammation and cancer. Nature 2002, 420, 860-867.
23. Shankaran, V.; Ikeda, H.; Bruce, A. T.; White, J. M.; Swanson, P. E.; Old, L. J.; Schreiber, R. D. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001, 410, 1107-1111.
24. Laheru, D.; Jaffee, E. M. Immunotherapy for pancreatic cancer - science driving clinical progress. Nat. Rev. Cancer 2005, 5, 459-467.
25. Jaffee, E. M.; Hruban, R. H.; Biedrzycki, B.; Laheru, D.; Schepers, K.; Sauter, P. R.; Goemann, M.; Coleman, J.; Grochow, L.; Donehower, R. C.; Lillemoe, K. D.; O'Reilly, S.; Abrams, R. A.; Pardoll, D. M.; Cameron, J. L.; Yeo, C. J. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J. Clin. Oncol. 2001, 19, 145-156.
26. Poch, B.; Lotspeich, E.; Ramadani, M.; Gansauge, S.; Beger, H. G.; Gansauge, F. Systemic immune dysfunction in pancreatic cancer patients. Langenbecks Arch. Surg. 2007, 392, 353-358.
27. Laheru, D.; Lutz, E.; Burke, J.; Biedrzycki, B.; Solt, S.; Onners, B.; Tartakovsky, I.; Nemunaitis, J.; Le, D.; Sugar, E.; Hege, K.; Jaffee, E. Allogeneic granulocyte macrophage colony-stimulating factorsecreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin. Cancer Res. 2008, 14, 1455-1463.
28. Tseng, J. F.; Willett, C. G.; Fernandez-del Castillo, C.; Ryan, D. P.; Clark, J. W.; Zhu, A. X.; Rattner, D. W.; Winkelmann, J. L.; Warshaw, A. L. Patients undergoing treatment for pancreatic adenocarcinoma can mount an effective immune response to vaccinations. Pancreatology 2005, 5, 67-74.
29. Schmitz-Winnenthal, F. H.; Escobedo, L. V.; Beckhove, P.; Schirrmacher, V.; Bucur, M.; Ziouta, Y.; Volk, C.; Schmied, B.; Koch, M.; Antolovic, D.; Weitz, J.; Buchler, M. W.; Z'Graggen, K. Specific immune recognition of pancreatic carcinoma by patientderived CD4 and CD8 T cells and its improvement by interferongamma. Int. J. Oncol. 2006, 28, 1419-1428.
30. Schmitz-Winnenthal, F. H.; Volk, C.; Z'Graggen, K.; Galindo, L.; Nummer, D.; Ziouta, Y.; Bucur, M.; Weitz, J.; Schirrmacher, V.; Buchler, M. W.; Beckhove, P. High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients. Cancer Res. 2005, 65, 10079-10087.
31. Kubuschok, B.; Neumann, F.; Breit, R.; Sester, M.; Schormann, C.; Wagner, C.; Sester, U.; Hartmann, F.; Wagner, M.; Remberger, K.; Schilling, M.; Pfreundschuh, M. Naturally occurring T-cell response against mutated p21 ras oncoprotein in pancreatic cancer. Clin. Cancer Res. 2006, 12, 1365-1372.
32. Thomas, A. M.; Santarsiero, L. M.; Lutz, E. R.; Armstrong, T. D.; Chen, Y. C.; Huang, L. Q.; Laheru, D. A.; Goggins, M.; Hruban, R. H.; Jaffee, E. M. Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J. Exp. Med. 2004, 200, 297-306.
33. Argani, P.; Iacobuzio-Donahue, C.; Ryu, B.; Rosty, C.; Goggins, M.; Wilentz, R. E.; Murugesan, S. R.; Leach, S. D.; Jaffee, E.; Yeo, C. J.; Cameron, J. L.; Kern, S. E.; Hruban, R. H. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin. Cancer Res. 2001, 7, 3862-3868.
34. Iacobuzio-Donahue, C. A.; Ashfaq, R.; Maitra, A.; Adsay, N. V.; Shen-Ong, G. L.; Berg, K.; Hollingsworth, M. A.; Cameron, J. L.; Yeo, C. J.; Kern, S. E.; Goggins, M.; Hruban, R. H. Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res. 2003, 63, 8614-8622.
35. Johnston, F. M.; Tan, M. C.; Tan, B. R., Jr.; Porembka, M. R.; Brunt, E. M.; Linehan, D. C.; Simon, P. O., Jr.; Plambeck-Suess, S.; Eberlein, T. J.; Hellstrom, K. E.; Hellstrom, I.; Hawkins, W. G.; Goedegebuure, P. Circulating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancer. Clin. Cancer Res. 2009, 15, 6511-6518.
36. Ikemoto, T.; Yamaguchi, T.; Morine, Y.; Imura, S.; Soejima, Y.; Fujii, M.; Maekawa, Y.; Yasutomo, K.; Shimada, M. Clinical roles of increased populations of Foxp3+CD4+ T cells in peripheral blood from advanced pancreatic cancer patients. Pancreas 2006, 33, 386-390.
37. Hiraoka, N.; Onozato, K.; Kosuge, T.; Hirohashi, S. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin. Cancer Res. 2006, 12, 5423-5434.
38. Nomi, T.; Sho, M.; Akahori, T.; Hamada, K.; Kubo, A.; Kanehiro, H.; Nakamura, S.; Enomoto, K.; Yagita, H.; Azuma, M.; Nakajima, Y. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin. Cancer Res. 2007, 13, 2151-2157.
39. Keir, M. E.; Butte, M. J.; Freeman, G. J.; Sharpe, A. H. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 2008, 26, 677-704.
40. Smyth, M. J.; Dunn, G. P.; Schreiber, R. D. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv. Immunol. 2006, 90, 1-50.
41. Mellor, A. L.; Munn, D. H. Creating immune privilege: active local suppression that benefits friends, but protects foes. Nat. Rev. Immunol. 2008, 8, 74-80.
42. Clark, C. E.; Beatty, G. L.; Vonderheide, R. H. Immunosurveillance of pancreatic adenocarcinoma: insights from genetically engineered mouse models of cancer. Cancer Lett. 2009, 279, 1-7.
43. Ungefroren, H.; Voss, M.; Bernstorff, W. V.; Schmid, A.; Kremer, B.; Kalthoff, H. Immunological escape mechanisms in pancreatic carcinoma. Ann. N. Y. Acad. Sci. 1999, 880, 243-251.
44. von Bernstorff, W.; Voss, M.; Freichel, S.; Schmid, A.; Vogel, I.; Johnk, C.; Henne-Bruns, D.; Kremer, B.; Kalthoff, H. Systemic and local immunosuppression in pancreatic cancer patients. Clin. Cancer Res. 2001, 7, 925s-932s.
45. Mellor, A. L.; Munn, D. H. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat. Rev. Immunol. 2004, 4, 762-774.
46. Gabrilovich, D. I.; Nagaraj, S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 2009, 9, 162-174.
47. Diaz-Montero, C. M.; Salem, M. L.; Nishimura, M. I.; Garrett-Mayer, E.; Cole, D. J.; Montero, A. J. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol. Immunother. 2009, 58, 49-59.
48. Young, M. R.; Newby, M.; Wepsic, H. T. Hematopoiesis and suppressor bone marrow cells in mice bearing large metastatic Lewis lung carcinoma tumors. Cancer Res. 1987, 47, 100-105.
49. Allison, A. C. Mechanisms by which activated macrophages inhibit lymphocyte responses. Immunol. Rev. 1978, 40, 3-27.
50. Ye, Q. W.; Mokyr, M. B.; Pyle, J. M.; Dray, S. Suppression of antitumor immunity by macrophages in spleens of mice bearing a large MOPC-315 tumor. Cancer Immunol. Immunother. 1984, 16, 162-169.
51. Hardy, C. L.; Balducci, L. Early hematopoietic events during tumor growth in mice. J. Natl. Cancer Inst. 1986, 76, 535-540.
52. Garrity, T.; Pandit, R.; Wright, M. A.; Benefield, J.; Keni, S.; Young, M. R. Increased presence of CD34+ cells in the peripheral blood of head and neck cancer patients and their differentiation into dendritic cells. Int. J. Cancer 1997, 73, 663-669.
53. Gabrilovich, D. I.; Chen, H. L.; Girgis, K. R.; Cunningham, H. T.; Meny, G. M.; Nadaf, S.; Kavanaugh, D.; Carbone, D. P. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 1996, 2, 1096-1103.
54. Marx, J. Cancer immunology. Cancer's bulwark against immune attack: MDS cells. Science 2008, 319, 154-156.
55. Gabrilovich, D. I.; Bronte, V.; Chen, S. H.; Colombo, M. P.; Ochoa, A.; Ostrand-Rosenberg, S.; Schreiber, H. The terminology issue for myeloid-derived suppressor cells. Cancer Res. 2007, 67, 425.
56. Greten, T. F.; Manns, M. P.; Korangy, F. Myeloid derived suppressor cells in human diseases. Int. Immunopharmacol. 2011 Epub date 2011/01/18
57. Zea, A. H.; Rodriguez, P. C.; Atkins, M. B.; Hernandez, C.; Signoretti, S.; Zabaleta, J.; McDermott, D.; Quiceno, D.; Youmans, A.; O'Neill, A.; Mier, J.; Ochoa, A. C. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res. 2005, 65, 3044-3048.
58. Rodriguez, P. C.; Ernstoff, M. S.; Hernandez, C.; Atkins, M.; Zabaleta, J.; Sierra, R.; Ochoa, A. C. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res. 2009, 69, 1553-1560.
59. Schmielau, J.; Finn, O. J. Activated granulocytes and granulocytederived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res. 2001, 61, 4756-4760.
60. Wang, Y. M.; Wang, C. L.; Feng, P. H.; Ko, H. W.; Liu, Y. H.; Wu, Y. C.; Chu, Y.; Chung, F. T.; Kuo, C. H.; Lee, K. Y.; Lin, S. M.; Lin, H. C.; Wang, C. H.; Yu, C. T.; Kuo, H. P. Population alterations of L: -arginase- and inducible nitric oxide synthaseexpressed CD11b(+)/CD14 (-)/CD15 (+)/CD33 (+) myeloidderivedsuppressor cells and CD8 (+) T lymphocytes in patients with advanced-stage non-small cell lung cancer. J. Cancer Res. Clin. Oncol. 2010, 136, 35-45.
61. Nemeth, M. J.; Bodine, D. M. Regulation of hematopoiesis and the hematopoietic stem cell niche by Wnt signaling pathways. Cell Res. 2007, 17, 746-758.
62. Delano, M. J.; Scumpia, P. O.; Weinstein, J. S.; Coco, D.; Nagaraj, S.; Kelly-Scumpia, K. M.; O'Malley, K. A.; Wynn, J. L.; Antonenko, S.; Al-Quran, S. Z.; Swan, R.; Chung, C. S.; Atkinson, M. A.; Ramphal, R.; Gabrilovich, D. I.; Reeves, W. H.; Ayala, A.; Phillips, J.; Laface, D.; Heyworth, P. G.; Clare-Salzler, M.; Moldawer, L. L. MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis. J. Exp. Med. 2007, 204, 1463-1474.
63. Makarenkova, V. P.; Bansal, V.; Matta, B. M.; Perez, L. A.; Ochoa, J. B. CD11b+/Gr-1+ myeloid suppressor cells cause T cell dysfunction after traumatic stress. J. Immunol. 2006, 176, 2085-2094.
64. Serafini, P.; Borrello, I.; Bronte, V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin. Cancer Biol. 2006, 16, 53-65.
65. Gallina, G.; Dolcetti, L.; Serafini, P.; De Santo, C.; Marigo, I.; Colombo, M. P.; Basso, G.; Brombacher, F.; Borrello, I.; Zanovello, P.; Bicciato, S.; Bronte, V. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J. Clin. Invest. 2006, 116, 2777-2790.
66. Gordon, S.; Taylor, P. R. Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 2005, 5, 953-964.
67. Lewis, C. E.; Pollard, J. W. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006, 66, 605-612.
68. Norian, L. A.; Rodriguez, P. C.; O'Mara, L. A.; Zabaleta, J.; Ochoa, A. C.; Cella, M.; Allen, P. M. Tumor-infiltrating regulatory dendritic cells inhibit CD8+ T cell function via L-arginine metabolism. Cancer Res. 2009, 69, 3086-3094.
69. Ma, G.; Pan, P. Y.; Eisenstein, S.; Divino, C. M.; Lowell, C. A.; Takai, T.; Chen, S. H. Paired immunoglobin-like receptor-B regulates the suppressive function and fate of myeloid-derived suppressor cells. Immunity 2011, 34, 385-395.
70. Biswas, S. K.; Gangi, L.; Paul, S.; Schioppa, T.; Saccani, A.; Sironi, M.; Bottazzi, B.; Doni, A.; Vincenzo, B.; Pasqualini, F.; Vago, L.; Nebuloni, M.; Mantovani, A.; Sica, A. A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood 2006, 107, 2112-2122.
71. Umemura, N.; Saio, M.; Suwa, T.; Kitoh, Y.; Bai, J.; Nonaka, K.; Ouyang, G. F.; Okada, M.; Balazs, M.; Adany, R.; Shibata, T.; Takami, T. Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics. J. Leukoc. Biol. 2008, 83, 1136-1144.
72. Youn, J. I.; Gabrilovich, D. I. The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur. J. Immunol. 2010, 40, 2969-2975.
73. Vieweg, J.; Su, Z.; Dahm, P.; Kusmartsev, S. Reversal of tumormediated immunosuppression. Clin. Cancer Res. 2007, 13, 727s-732s.
74. Almand, B.; Clark, J. I.; Nikitina, E.; van Beynen, J.; English, N. R.; Knight, S. C.; Carbone, D. P.; Gabrilovich, D. I. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J. Immunol. 2001, 166, 678-689.
75. Peranzoni, E.; Zilio, S.; Marigo, I.; Dolcetti, L.; Zanovello, P.; Mandruzzato, S.; Bronte, V. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr. Opin. Immunol. 2010, 22, 238-244.
76. Brandau, S.; Trellakis, S.; Bruderek, K.; Schmaltz, D.; Steller, G.; Elian, M.; Suttmann, H.; Schenck, M.; Welling, J.; Zabel, P.; Lang, S. Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties. J. Leukoc. Biol. 2011, 89, 311-317.
77. Hoechst, B.; Ormandy, L. A.; Ballmaier, M.; Lehner, F.; Kruger, C.; Manns, M. P.; Greten, T. F.; Korangy, F. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology 2008, 135, 234-243.
78. Filipazzi, P.; Valenti, R.; Huber, V.; Pilla, L.; Canese, P.; Iero, M.; Castelli, C.; Mariani, L.; Parmiani, G.; Rivoltini, L. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J. Clin. Oncol. 2007, 25, 2546-2553.
79. Poschke, I.; Mougiakakos, D.; Hansson, J.; Masucci, G. V.; Kiessling, R. Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res. 2010, 70, 4335-4345.
80. Brimnes, M. K.; Vangsted, A. J.; Knudsen, L. M.; Gimsing, P.; Gang, A. O.; Johnsen, H. E.; Svane, I. M. Increased level of both CD4+FOXP3+ regulatory T cells and CD14+HLA-DR/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma. Scand. J. Immunol. 2010, 72, 540-547.
81. Gustafson, M. P.; Lin, Y.; New, K. C.; Bulur, P. A.; O'Neill, B. P.; Gastineau, D. A.; Dietz, A. B. Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone. Neuro. Oncol. 2010, 12, 631-644.
82. Loercher, A. E.; Nash, M. A.; Kavanagh, J. J.; Platsoucas, C. D.; Freedman, R. S. Identification of an IL-10-producing HLA-DR negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells. J. Immunol. 1999, 163, 6251-6260.
83. Ugurel, S.; Uhlig, D.; Pfohler, C.; Tilgen, W.; Schadendorf, D.; Reinhold, U. Down-regulation of HLA class II and costimulatory CD86/B7-2 on circulating monocytes from melanoma patients. Cancer Immunol. Immunother. 2004, 53, 551-559.
84. Herr, H. W. Suppressor cells in immunodepressed bladder and prostate cancer patients. J. Urol. 1980, 123, 635-639.
85. Vuk-Pavlovic, S.; Bulur, P. A.; Lin, Y.; Qin, R.; Szumlanski, C. L.; Zhao, X.; Dietz, A. B. Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer. Prostate 2010, 70, 443-455.
86. Movahedi, K.; Guilliams, M.; Van den Bossche, J.; Van den Bergh, R.; Gysemans, C.; Beschin, A.; De Baetselier, P.; Van Ginderachter, J. A. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 2008, 111, 4233-4244.
87. Youn, J. I.; Nagaraj, S.; Collazo, M.; Gabrilovich, D. I. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J. Immunol. 2008, 181, 5791-5802.
88. Gabrilovich, D. I.; Velders, M. P.; Sotomayor, E. M.; Kast, W. M. Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J. Immunol. 2001, 166, 5398-5406.
89. Dolcetti, L.; Peranzoni, E.; Ugel, S.; Marigo, I.; Fernandez Gomez, A.; Mesa, C.; Geilich, M.; Winkels, G.; Traggiai, E.; Casati, A.; Grassi, F.; Bronte, V. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur. J. Immunol. 2010, 40, 22-35.
90. Corzo, C. A.; Condamine, T.; Lu, L.; Cotter, M. J.; Youn, J. I.; Cheng, P.; Cho, H. I.; Celis, E.; Quiceno, D. G.; Padhya, T.; McCaffrey, T. V.; McCaffrey, J. C.; Gabrilovich, D. I. HIF-1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J. Exp. Med. 2010, 207, 2439-2453.
91. Kusmartsev, S.; Nagaraj, S.; Gabrilovich, D. I. Tumor-associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells. J. Immunol. 2005, 175, 4583-4592.
92. Elgert, K. D.; Alleva, D. G.; Mullins, D. W. Tumor-induced immune dysfunction: the macrophage connection. J. Leukoc. Biol. 1998, 64, 275-290.
93. Huang, B.; Pan, P. Y.; Li, Q.; Sato, A. I.; Levy, D. E.; Bromberg, J.; Divino, C. M.; Chen, S. H. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 2006, 66, 1123-1131.
94. Solito, S.; Bronte, V.; Mandruzzato, S. Antigen specificity of immune suppression by myeloid-derived suppressor cells. J. Leukoc. Biol. 2011, (Epub ahead of print; April 14, 2011).
95. Almand, B.; Resser, J. R.; Lindman, B.; Nadaf, S.; Clark, J. I.; Kwon, E. D.; Carbone, D. P.; Gabrilovich, D. I. Clinical significance of defective dendritic cell differentiation in cancer. Clin. Cancer Res 2000, 6, 1755-1766.
96. Corzo, C. A.; Cotter, M. J.; Cheng, P.; Cheng, F.; Kusmartsev, S.; Sotomayor, E.; Padhya, T.; McCaffrey, T. V.; McCaffrey, J. C.; Gabrilovich, D. I. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J. Immunol. 2009, 182, 5693-5701.
97. Ostrand-Rosenberg, S.; Sinha, P. Myeloid-derived suppressor cells: linking inflammation and cancer. J. Immunol. 2009, 182, 4499-4506.
98. Marigo, I.; Dolcetti, L.; Serafini, P.; Zanovello, P.; Bronte, V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol. Rev. 2008, 222, 162-179.
99. Ko, J. S.; Zea, A. H.; Rini, B. I.; Ireland, J. L.; Elson, P.; Cohen, P.; Golshayan, A.; Rayman, P. A.; Wood, L.; Garcia, J.; Dreicer, R.; Bukowski, R.; Finke, J. H. Sunitinib mediates reversal of myeloidderived suppressor cell accumulation in renal cell carcinoma patients. Clin. Cancer Res. 2009, 15, 2148-2157.
100. Kusmartsev, S.; Su, Z.; Heiser, A.; Dannull, J.; Eruslanov, E.; Kubler, H.; Yancey, D.; Dahm, P.; Vieweg, J. Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin. Cancer Res. 2008, 14, 8270-8278.
101. Haverkamp, J. M.; Crist, S. A.; Elzey, B. D.; Cimen, C.; Ratliff, T. L. In vivo suppressive function of myeloid-derived suppressor cells is limited to the inflammatory site. Eur. J. Immunol. 2011, 41, 749-759.
102. Grizzle, W. E.; Xu, X.; Zhang, S.; Stockard, C. R.; Liu, C.; Yu, S.; Wang, J.; Mountz, J. D.; Zhang, H. G. Age-related increase of tumor susceptibility is associated with myeloid-derived suppressor cell mediated suppression of T cell cytotoxicity in recombinant inbred BXD12 mice. Mech. Ageing Dev. 2007, 128, 672-680.
103. Li, H.; Han, Y.; Guo, Q.; Zhang, M.; Cao, X. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J. Immunol. 2009, 182, 240-249.
104. Nausch, N.; Galani, I. E.; Schlecker, E.; Cerwenka, A. Mononuclear myeloid-derived suppressor cells express RAE-1 and activate natural killer cells. Blood 2008, 112, 4080-4089.
105. Terabe, M.; Berzofsky, J. A. The role of NKT cells in tumor immunity. Adv. Cancer Res. 2008, 101, 277-348.
106. Sinha, P.; Clements, V. K.; Ostrand-Rosenberg, S. Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. Cancer Res. 2005, 65, 11743-11751.
107. Sinha, P.; Clements, V. K.; Bunt, S. K.; Albelda, S. M.; Ostrand-Rosenberg, S. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J. Immunol. 2007, 179, 977-983.
108. Hoechst, B.; Gamrekelashvili, J.; Manns, M. P.; Greten, T. F.; Korangy, F. Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells. Blood 2011. Epub ahead of print; April 14, 2011
109. Clark, C. E.; Hingorani, S. R.; Mick, R.; Combs, C.; Tuveson, D. A.; Vonderheide, R. H. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res. 2007, 67, 9518-9527.
110. Lu, L. F.; Lind, E. F.; Gondek, D. C.; Bennett, K. A.; Gleeson, M. W.; Pino-Lagos, K.; Scott, Z. A.; Coyle, A. J.; Reed, J. L.; Van Snick, J.; Strom, T. B.; Zheng, X. X.; Noelle, R. J. Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature 2006, 442, 997-1002.
111. Steinbrink, K.; Mahnke, K.; Grabbe, S.; Enk, A. H.; Jonuleit, H. Myeloid dendritic cell: From sentinel of immunity to key player of peripheral tolerance? Hum. Immunol. 2009, 70, 289-293.
112. Ghiringhelli, F.; Puig, P. E.; Roux, S.; Parcellier, A.; Schmitt, E.; Solary, E.; Kroemer, G.; Martin, F.; Chauffert, B.; Zitvogel, L. Tumor cells convert immature myeloid dendritic cells into TGFbeta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J. Exp. Med. 2005, 202, 919-929.
113. Hori, S.; Nomura, T.; Sakaguchi, S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299, 1057-1061.
114. Sakaguchi, S.; Sakaguchi, N.; Asano, M.; Itoh, M.; Toda, M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 1995, 155, 1151-1164.
115. Fontenot, J. D.; Gavin, M. A.; Rudensky, A. Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 2003, 4, 330-336.
116. Khattri, R.; Cox, T.; Yasayko, S. A.; Ramsdell, F. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat. Immunol. 2003, 4, 337-342.
117. Linehan, D. C.; Goedegebuure, P. S. CD25+ CD4+ regulatory Tcells in cancer. Immunol. Res. 2005, 32, 155-168.
118. Onizuka, S.; Tawara, I.; Shimizu, J.; Sakaguchi, S.; Fujita, T.; Nakayama, E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res. 1999, 59, 3128-3133.
119. Shimizu, J.; Yamazaki, S.; Sakaguchi, S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 1999, 163, 5211-5218.
120. Liyanage, U. K.; Moore, T. T.; Joo, H. G.; Tanaka, Y.; Herrmann, V.; Doherty, G.; Drebin, J. A.; Strasberg, S. M.; Eberlein, T. J.; Goedegebuure, P. S.; Linehan, D. C. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 2002, 169, 2756-2761.
121. Fu, J.; Xu, D.; Liu, Z.; Shi, M.; Zhao, P.; Fu, B.; Zhang, Z.; Yang, H.; Zhang, H.; Zhou, C.; Yao, J.; Jin, L.; Wang, H.; Yang, Y.; Fu, Y. X.; Wang, F. S. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 2007, 132, 2328-2339.
122. Curiel, T. J.; Coukos, G.; Zou, L.; Alvarez, X.; Cheng, P.; Mottram, P.; Evdemon-Hogan, M.; Conejo-Garcia, J. R.; Zhang, L.; Burow, M.; Zhu, Y.; Wei, S.; Kryczek, I.; Daniel, B.; Gordon, A.; Myers, L.; Lackner, A.; Disis, M. L.; Knutson, K. L.; Chen, L.; Zou, W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 2004, 10, 942-949.
123. Kusmartsev, S.; Gabrilovich, D. I. Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species. J. Leukoc. Biol. 2003, 74, 186-196.
124. Nagaraj, S.; Gupta, K.; Pisarev, V.; Kinarsky, L.; Sherman, S.; Kang, L.; Herber, D. L.; Schneck, J.; Gabrilovich, D. I. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat. Med. 2007, 13, 828-835.
125. Nagaraj, S.; Schrum, A. G.; Cho, H. I.; Celis, E.; Gabrilovich, D. I. Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J. Immunol. 2010, 184, 3106-3116.
126. Rodriguez, P. C.; Quiceno, D. G.; Zabaleta, J.; Ortiz, B.; Zea, A. H.; Piazuelo, M. B.; Delgado, A.; Correa, P.; Brayer, J.; Sotomayor, E. M.; Antonia, S.; Ochoa, J. B.; Ochoa, A. C. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigenspecific T-cell responses. Cancer Res. 2004, 64, 5839-5849.
127. Zhu, B.; Bando, Y.; Xiao, S.; Yang, K.; Anderson, A. C.; Kuchroo, V. K.; Khoury, S. J. CD11b+Ly-6C(hi) suppressive monocytes in experimental autoimmune encephalomyelitis. J. Immunol. 2007, 179, 5228-5237.
128. Bronte, V.; Zanovello, P. Regulation of immune responses by Larginine metabolism. Nat. Rev. Immunol. 2005, 5, 641-654.
129. Rodriguez, P. C.; Ochoa, A. C. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol. Rev. 2008, 222, 180-191.
130. Solinas, G.; Germano, G.; Mantovani, A.; Allavena, P. Tumorassociated macrophages (TAM) as major players of the cancerrelated inflammation. J.Leukoc. Biol. 2009, 86, 1065-1073.
131. Srivastava, M. K.; Sinha, P.; Clements, V. K.; Rodriguez, P.; Ostrand-Rosenberg, S. Myeloid-derived suppressor cells inhibit Tcell activation by depleting cystine and cysteine. Cancer Res. 2010, 70, 68-77.
132. Ostrand-Rosenberg, S. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol. Immunother. 2010, 59, 1593-1600.
133. Hanson, E. M.; Clements, V. K.; Sinha, P.; Ilkovitch, D.; Ostrand-Rosenberg, S. Myeloid-derived suppressor cells down-regulate Lselectin expression on CD4+ and CD8+ T cells. J. Immunol. 2009, 183, 937-944.
134. Kryczek, I.; Zou, L.; Rodriguez, P.; Zhu, G.; Wei, S.; Mottram, P.; Brumlik, M.; Cheng, P.; Curiel, T.; Myers, L.; Lackner, A.; Alvarez, X.; Ochoa, A.; Chen, L.; Zou, W. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J. Exp. Med. 2006, 203, 871-881.
135. Curiel, T. J.; Wei, S.; Dong, H.; Alvarez, X.; Cheng, P.; Mottram, P.; Krzysiek, R.; Knutson, K. L.; Daniel, B.; Zimmermann, M. C.; David, O.; Burow, M.; Gordon, A.; Dhurandhar, N.; Myers, L.; Berggren, R.; Hemminki, A.; Alvarez, R. D.; Emilie, D.; Curiel, D. T.; Chen, L.; Zou, W. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 2003, 9, 562-567.
136. Kuang, D. M.; Zhao, Q.; Peng, C.; Xu, J.; Zhang, J. P.; Wu, C.; Zheng, L. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J. Exp. Med. 2009, 206, 1327-1337.
137. Murdoch, C.; Muthana, M.; Coffelt, S. B.; Lewis, C. E. The role of myeloid cells in the promotion of tumour angiogenesis. Nat. Rev. Cancer 2008, 8, 618-631.
138. Yang, L.; DeBusk, L. M.; Fukuda, K.; Fingleton, B.; Green-Jarvis, B.; Shyr, Y.; Matrisian, L. M.; Carbone, D. P.; Lin, P. C. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004, 6, 409-421.
139. Yang, L.; Huang, J.; Ren, X.; Gorska, A. E.; Chytil, A.; Aakre, M.; Carbone, D. P.; Matrisian, L. M.; Richmond, A.; Lin, P. C.; Moses, H. L. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 2008, 13, 23-35.
140. Kaplan, R. N.; Riba, R. D.; Zacharoulis, S.; Bramley, A. H.; Vincent, L.; Costa, C.; MacDonald, D. D.; Jin, D. K.; Shido, K.; Kerns, S. A.; Zhu, Z.; Hicklin, D.; Wu, Y.; Port, J. L.; Altorki, N.; Port, E. R.; Ruggero, D.; Shmelkov, S. V.; Jensen, K. K.; Rafii, S.; Lyden, D. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005, 438, 820-827.
141. Psaila, B.; Lyden, D. The metastatic niche: adapting the foreign soil. Nat. Rev. Cancer 2009, 9, 285-293.
142. Connolly, M. K.; Mallen-St Clair, J.; Bedrosian, A. S.; Malhotra, A.; Vera, V.; Ibrahim, J.; Henning, J.; Pachter, H. L.; Bar-Sagi, D.; Frey, A. B.; Miller, G. Distinct populations of metastases-enabling myeloid cells expand in the liver of mice harboring invasive and preinvasive intra-abdominal tumor. J. Leukoc. Biol. 2010, 87, 713-725.
143. Melani, C.; Chiodoni, C.; Forni, G.; Colombo, M. P. Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood 2003, 102, 2138-2145.
144. Kusmartsev, S.; Eruslanov, E.; Kubler, H.; Tseng, T.; Sakai, Y.; Su, Z.; Kaliberov, S.; Heiser, A.; Rosser, C.; Dahm, P.; Siemann, D.; Vieweg, J. Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma. J. Immunol. 2008, 181, 346-353.
145. Melani, C.; Sangaletti, S.; Barazzetta, F. M.; Werb, Z.; Colombo, M. P. Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res. 2007, 67, 11438-11446.
146. Pahler, J. C.; Tazzyman, S.; Erez, N.; Chen, Y. Y.; Murdoch, C.; Nozawa, H.; Lewis, C. E.; Hanahan, D. Plasticity in tumorpromoting inflammation: impairment of macrophage recruitment evokes a compensatory neutrophil response. Neoplasia 2008, 10, 329-340.
147. Bergers, G.; Hanahan, D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 2008, 8, 592-603.
148. Hiratsuka, S.; Watanabe, A.; Aburatani, H.; Maru, Y. Tumourmediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat. Cell. Biol. 2006, 8, 1369-1375.
149. Rafii, S.; Lyden, D. S100 chemokines mediate bookmarking of premetastatic niches. Nat. Cell Biol. 2006, 8, 1321-1323.
150. Newton, R. A.; Hogg, N. The human S100 protein MRP-14 is a novel activator of the beta 2 integrin Mac-1 on neutrophils. J. Immunol. 1998, 160, 1427-1435.
151. Sinha, P.; Okoro, C.; Foell, D.; Freeze, H. H.; Ostrand-Rosenberg, S.; Srikrishna, G. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J. Immunol. 2008, 181, 4666-4675.
152. Cheng, P.; Corzo, C. A.; Luetteke, N.; Yu, B.; Nagaraj, S.; Bui, M. M.; Ortiz, M.; Nacken, W.; Sorg, C.; Vogl, T.; Roth, J.; Gabrilovich, D. I. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J. Exp. Med. 2008, 205, 2235-2249.
153. Hiratsuka, S.; Watanabe, A.; Sakurai, Y.; Akashi-Takamura, S.; Ishibashi, S.; Miyake, K.; Shibuya, M.; Akira, S.; Aburatani, H.; Maru, Y. The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat. Cell Biol. 2008, 10, 1349-1355.
154. Matsuo, Y.; Ochi, N.; Sawai, H.; Yasuda, A.; Takahashi, H.; Funahashi, H.; Takeyama, H.; Tong, Z.; Guha, S. CXCL8/IL-8 and CXCL12/SDF-1alpha co-operatively promote invasiveness and angiogenesis in pancreatic cancer. Int. J. Cancer 2009, 124, 853-861.
155. Kucia, M.; Reca, R.; Miekus, K.; Wanzeck, J.; Wojakowski, W.; Janowska-Wieczorek, A.; Ratajczak, J.; Ratajczak, M. Z. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells 2005, 23, 879-894.
156. Marechal, R.; Demetter, P.; Nagy, N.; Berton, A.; Decaestecker, C.; Polus, M.; Closset, J.; Deviere, J.; Salmon, I.; Van Laethem, J. L. High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma. Br. J. Cancer 2009, 100, 1444-1451.
157. Burger, J. A.; Kipps, T. J. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 2006, 107, 1761-1767.
158. Huang, B.; Lei, Z.; Zhao, J.; Gong, W.; Liu, J.; Chen, Z.; Liu, Y.; Li, D.; Yuan, Y.; Zhang, G. M.; Feng, Z. H. CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Lett. 2007, 252, 86-92.
159. Bunt, S. K.; Clements, V. K.; Hanson, E. M.; Sinha, P.; Ostrand-Rosenberg, S. Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through Toll-like receptor 4. J. Leukoc. Biol. 2009, 85, 996-1004.
160. Bunt, S. K.; Yang, L.; Sinha, P.; Clements, V. K.; Leips, J.; Ostrand-Rosenberg, S. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res. 2007, 67, 10019-10026.
161. Tu, S.; Bhagat, G.; Cui, G.; Takaishi, S.; Kurt-Jones, E. A.; Rickman, B.; Betz, K. S.; Penz-Oesterreicher, M.; Bjorkdahl, O.; Fox, J. G.; Wang, T. C. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloidderived suppressor cells in mice. Cancer Cell 2008, 14, 408-419.
162. Bronte, V.; Chappell, D. B.; Apolloni, E.; Cabrelle, A.; Wang, M.; Hwu, P.; Restifo, N. P. Unopposed production of granulocytemacrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. J. Immunol. 1999, 162, 5728-5737.
163. Markiewski, M. M.; DeAngelis, R. A.; Benencia, F.; Ricklin-Lichtsteiner, S. K.; Koutoulaki, A.; Gerard, C.; Coukos, G.; Lambris, J. D. Modulation of the antitumor immune response by complement. Nat. Immunol. 2008, 9, 1225-1235.
164. Serafini, P.; De Santo, C.; Marigo, I.; Cingarlini, S.; Dolcetti, L.; Gallina, G.; Zanovello, P.; Bronte, V. Derangement of immune responses by myeloid suppressor cells. Cancer Immunol. Immunother. 2004, 53, 64-72.
165. Eruslanov, E.; Daurkin, I.; Ortiz, J.; Vieweg, J.; Kusmartsev, S. Pivotal Advance: Tumor-mediated induction of myeloid-derived suppressor cells and M2-polarized macrophages by altering intracellular PGE catabolism in myeloid cells. J. Leukoc. Biol. 2010, 88, 839-848.
166. Chornoguz, O.; Grmai, L.; Sinha, P.; Artemenko, K.; Zubarev, R.; Ostrand-Rosenberg, S. Proteomic pathway analysis reveals inflammation increases myeloid-derived suppressor cell resistance to apoptosis. Mol. Cell. Proteomics 2011, 10, 1-9.
167. Lechner, M. G.; Liebertz, D. J.; Epstein, A. L. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J. Immunol. 2010, 185, 2273-2284.
168. Bunt, S. K.; Sinha, P.; Clements, V. K.; Leips, J.; Ostrand-Rosenberg, S. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J. Immunol. 2006, 176, 284-290.
169. Song, X.; Krelin, Y.; Dvorkin, T.; Bjorkdahl, O.; Segal, S.; Dinarello, C. A.; Voronov, E.; Apte, R. N. CD11b+/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1beta-secreting cells. J. Immunol. 2005, 175, 8200-8208.
170. Nefedova, Y.; Huang, M.; Kusmartsev, S.; Bhattacharya, R.; Cheng, P.; Salup, R.; Jove, R.; Gabrilovich, D. Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J. Immunol. 2004, 172, 464-474.
171. Ehrchen, J. M.; Sunderkotter, C.; Foell, D.; Vogl, T.; Roth, J. The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J. Leukoc. Biol. 2009, 86, 557-566.
172. Mazzoni, A.; Bronte, V.; Visintin, A.; Spitzer, J. H.; Apolloni, E.; Serafini, P.; Zanovello, P.; Segal, D. M. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J. Immunol. 2002, 168, 689-695.
173. Bronte, V.; Serafini, P.; De Santo, C.; Marigo, I.; Tosello, V.; Mazzoni, A.; Segal, D. M.; Staib, C.; Lowel, M.; Sutter, G.; Colombo, M. P.; Zanovello, P. IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J. Immunol. 2003, 170, 270-278.
174. Zhang, B.; Zhang, Y.; Bowerman, N. A.; Schietinger, A.; Fu, Y. X.; Kranz, D. M.; Rowley, D. A.; Schreiber, H. Equilibrium between host and cancer caused by effector T cells killing tumor stroma. Cancer Res. 2008, 68, 1563-1571.
175. Kao, J.; Ko, E. C.; Eisenstein, S.; Sikora, A. G.; Fu, S.; Chen, S. H. Targeting immune suppressing myeloid-derived suppressor cells in oncology. Crit. Rev. Oncol. Hematol. 2011, 77, 12-19.
176. Vincent, J.; Mignot, G.; Chalmin, F.; Ladoire, S.; Bruchard, M.; Chevriaux, A.; Martin, F.; Apetoh, L.; Rebe, C.; Ghiringhelli, F. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 2010, 70, 3052-3061.
177. Steding, C. E.; Wu, S. T.; Zhang, Y.; Jeng, M. H.; Elzey, B. D.; Kao, C. The role of interleukin-12 on modulating myeloid-derived suppressor cells, increasing overall survival and reducing metastasis. Immunology 2011, 133, 221-238.
178. Mirza, N.; Fishman, M.; Fricke, I.; Dunn, M.; Neuger, A. M.; Frost, T. J.; Lush, R. M.; Antonia, S.; Gabrilovich, D. I. All-transretinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res. 2006, 66, 9299-9307.
179. Lathers, D. M.; Clark, J. I.; Achille, N. J.; Young, M. R. Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D3. Cancer Immunol. Immunother. 2004, 53, 422-430.
180. Daud, A. I.; Mirza, N.; Lenox, B.; Andrews, S.; Urbas, P.; Gao, G. X.; Lee, J. H.; Sondak, V. K.; Riker, A. I.; Deconti, R. C.; Gabrilovich, D. Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor. J. Clin. Oncol. 2008, 26, 3235-3241.
181. Pan, P. Y.; Wang, G. X.; Yin, B.; Ozao, J.; Ku, T.; Divino, C. M.; Chen, S. H. Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood 2008, 111, 219-228.
182. Fricke, I.; Mirza, N.; Dupont, J.; Lockhart, C.; Jackson, A.; Lee, J. H.; Sosman, J. A.; Gabrilovich, D. I. Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Clin. Cancer Res. 2007, 13, 4840-4848.
183. Nagaraj, S.; Youn, J. I.; Weber, H.; Iclozan, C.; Lu, L.; Cotter, M. J.; Meyer, C.; Becerra, C. R.; Fishman, M.; Antonia, S.; Sporn, M. B.; Liby, K. T.; Rawal, B.; Lee, J. H.; Gabrilovich, D. I. Antiinflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. Clin. Cancer Res. 2010, 16, 1812-1823.
184. Talmadge, J. E.; Hood, K. C.; Zobel, L. C.; Shafer, L. R.; Coles, M.; Toth, B. Chemoprevention by cyclooxygenase-2 inhibition reduces immature myeloid suppressor cell expansion. Int. Immunopharmacol. 2007, 7, 140-151.
185. Mukherjee, P.; Basu, G. D.; Tinder, T. L.; Subramani, D. B.; Bradley, J. M.; Arefayene, M.; Skaar, T.; De Petris, G. Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition. J. Immunol. 2009, 182, 216-224.
186. Rodriguez, P. C.; Hernandez, C. P.; Quiceno, D.; Dubinett, S. M.; Zabaleta, J.; Ochoa, J. B.; Gilbert, J.; Ochoa, A. C. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J. Exp. Med. 2005, 202, 931-939.
187. Ko, H. J.; Kim, Y. J.; Kim, Y. S.; Chang, W. S.; Ko, S. Y.; Chang, S. Y.; Sakaguchi, S.; Kang, C. Y. A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res. 2007, 67, 7477-7486.
188. Degos, L.; Dombret, H.; Chomienne, C.; Daniel, M. T.; Miclea, J. M.; Chastang, C.; Castaigne, S.; Fenaux, P. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood 1995, 85, 2643-2653.
189. Miyauchi, J. All-trans retinoic acid and hematopoietic growth factors regulating the growth and differentiation of blast progenitors in acute promyelocytic leukemia. Leuk. Lymphoma 1999, 33, 267-280.
190. Serafini, P.; Carbley, R.; Noonan, K. A.; Tan, G.; Bronte, V.; Borrello, I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res. 2004, 64, 6337-6343.
191. Roskoski, R., Jr.; Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem. Biophys. Res. Commun. 2007, 356, 323-328.
192. Serafini, P.; Meckel, K.; Kelso, M.; Noonan, K.; Califano, J.; Koch, W.; Dolcetti, L.; Bronte, V.; Borrello, I. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J. Exp. Med. 2006, 203, 2691-2702.
193. Capuano, G.; Rigamonti, N.; Grioni, M.; Freschi, M.; Bellone, M. Modulators of arginine metabolism support cancer immunosurveillance. B.M.C. Immunol. 2009, 10, 1-13.
194. Fleisch, H. Development of bisphosphonates. Breast Cancer Res. 2002, 4, 30-34.
195. Santini, D.; Galluzzo, S.; Vincenzi, B.; Schiavon, G.; Fratto, E.; Pantano, F.; Tonini, G. New developments of aminobisphosphonates: the double face of Janus. Ann. Oncol. 2007, 18 (Suppl 6), vi164-vi167.
196. Tassone, P.; Tagliaferri, P.; Viscomi, C.; Palmieri, C.; Caraglia, M.; D'Alessandro, A.; Galea, E.; Goel, A.; Abbruzzese, A.; Boland, C. R.; Venuta, S. Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. Br. J. Cancer 2003, 88, 1971-1978.
197. Marten, A.; Lilienfeld-Toal, M.; Buchler, M. W.; Schmidt, J. Zoledronic acid has direct antiproliferative and antimetastatic effect on pancreatic carcinoma cells and acts as an antigen for delta2 gamma/delta T cells. J. Immunother. 2007, 30, 370-377.
198. Ferretti, G.; Fabi, A.; Carlini, P.; Papaldo, P.; Cordiali Fei, P.; Di Cosimo, S.; Salesi, N.; Giannarelli, D.; Alimonti, A.; Di Cocco, B.; D'Agosto, G.; Bordignon, V.; Trento, E.; Cognetti, F. Zoledronicacid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients. Oncology 2005, 69, 35-43.
199. Giraudo, E.; Inoue, M.; Hanahan, D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J. Clin. Invest. 2004, 114, 623-633.
200. Santini, D.; Vincenzi, B.; Dicuonzo, G.; Avvisati, G.; Massacesi, C.; Battistoni, F.; Gavasci, M.; Rocci, L.; Tirindelli, M. C.; Altomare, V.; Tocchini, M.; Bonsignori, M.; Tonini, G. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin. Cancer Res. 2003, 9, 2893-2897.
201. Santini, D.; Vincenzi, B.; Galluzzo, S.; Battistoni, F.; Rocci, L.; Venditti, O.; Schiavon, G.; Angeletti, S.; Uzzalli, F.; Caraglia, M.; Dicuonzo, G.; Tonini, G. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin. Cancer Res. 2007, 13, 4482-4486.
202. Zou, L.; Barnett, B.; Safah, H.; Larussa, V. F.; Evdemon-Hogan, M.; Mottram, P.; Wei, S.; David, O.; Curiel, T. J.; Zou, W. Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals. Cancer Res. 2004, 64, 8451-8455.
203. Hirbe, A. C.; Rubin, J.; Uluckan, O.; Morgan, E. A.; Eagleton, M. C.; Prior, J. L.; Piwnica-Worms, D.; Weilbaecher, K. N. Disruption of CXCR4 enhances osteoclastogenesis and tumor growth in bone. Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 14062-14067.
204. Hingorani, S. R.; Petricoin, E. F.; Maitra, A.; Rajapakse, V.; King, C.; Jacobetz, M. A.; Ross, S.; Conrads, T. P.; Veenstra, T. D.; Hitt, B. A.; Kawaguchi, Y.; Johann, D.; Liotta, L. A.; Crawford, H. C.; Putt, M. E.; Jacks, T.; Wright, C. V.; Hruban, R. H.; Lowy, A. M.; Tuveson, D. A. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003, 4, 437-450.
205. Zhao, F.; Obermann, S.; von Wasielewski, R.; Haile, L.; Manns, M. P.; Korangy, F.; Greten, T. F. Increase in frequency of myeloidderived suppressor cells in mice with spontaneous pancreatic carcinoma. Immunology 2009, 128, 141-149.
206. Hingorani, S. R.; Wang, L.; Multani, A. S.; Combs, C.; Deramaudt, T. B.; Hruban, R. H.; Rustgi, A. K.; Chang, S.; Tuveson, D. A. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005, 7, 469-483.